First-Line Lorlatinib or Crizotinib in Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Lung Cancer
Pfizer
Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon; CROWN Trial Investigators